Substance / Medication

Givosiran

Overview

Active Ingredient
givosiran
RxNorm CUI
2265712

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
Mazzoli M, Ricci A, Vaudano A E et al. · Eur Rev Med Pharmacol Sci · 2024
PMID: 38708485Case Report
Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria.
Bujold Kenneth E, Kasher Nicole, McKiernan Christine · J Pediatr Hematol Oncol · 2024
PMID: 39177802Case ReportFull text (PMC)
Hereditary Coproporphyria in Which the Patient's Course Improved after the Discontinuation of Givosiran.
Ozaki Nobuaki, Hayashi Yuri, Kiyota Atsushi · Intern Med · 2024
PMID: 38462517Case ReportFull text (PMC)
Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation.
Guida Claudio Carmine, Nardella Maria, Del Mar Ys Perez Aurora et al. · Mol Genet Metab Rep · 2024
PMID: 39027010Case ReportFull text (PMC)
Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-An ongoing clinical conundrum.
Ma Christopher D, Faust Denise, Bonkovsky Herbert L · JIMD Rep · 2023
PMID: 36873084Case ReportFull text (PMC)
Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
Graff Erica, Anderson Karl E, Levy Cynthia · Front Genet · 2022
PMID: 35991568Case ReportFull text (PMC)
Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran.
Steinberg Tim, Kilic Mustafa, Fuchs Kornelius et al. · J Neurol Sci · 2021
PMID: 33581419Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Givosiran (substance)
SNOMED CT
830239005
UMLS CUI
C4688584
RxNorm CUI
2265712

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.